Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

1.990 -0.110 (-5.24%)
Streaming Delayed Price Updated: 11:01 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces Patent Issuance
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds
From Enveric Biosciences, Inc
Via Business Wire
News headline image
Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Reverse Stock Split
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences to Explore Digital Asset Treasury Opportunities
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Participation in 2025 BIO International Convention
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003
From Enveric Biosciences
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.